MAP2K1 and neuroblastoma: Consistent with the notion of an LGR5-Ras-MEK/ERK axis, we have observed that treatment of our NB cell lines with Trametinib/GSK1120212 [53], a potent inhibitor of MEK1/2, leads to a rapid elimination of LGR5 (data not shown).